1例难治性原发中枢弥漫大B细胞淋巴瘤CAR-T细胞治疗中的多学科联合诊治

寇海明, 卢聪, 李成功, 等. 1例难治性原发中枢弥漫大B细胞淋巴瘤CAR-T细胞治疗中的多学科联合诊治[J]. 临床血液学杂志, 2022, 35(9): 621-625. doi: 10.13201/j.issn.1004-2806.2022.09.004
引用本文: 寇海明, 卢聪, 李成功, 等. 1例难治性原发中枢弥漫大B细胞淋巴瘤CAR-T细胞治疗中的多学科联合诊治[J]. 临床血液学杂志, 2022, 35(9): 621-625. doi: 10.13201/j.issn.1004-2806.2022.09.004
KOU Haiming, LU Cong, LI Chenggong, et al. Multidisciplinary treatment combination in CAR-T therapy for refractory primary central nerves system diffuse large B-cell lymphoma[J]. J Clin Hematol, 2022, 35(9): 621-625. doi: 10.13201/j.issn.1004-2806.2022.09.004
Citation: KOU Haiming, LU Cong, LI Chenggong, et al. Multidisciplinary treatment combination in CAR-T therapy for refractory primary central nerves system diffuse large B-cell lymphoma[J]. J Clin Hematol, 2022, 35(9): 621-625. doi: 10.13201/j.issn.1004-2806.2022.09.004

1例难治性原发中枢弥漫大B细胞淋巴瘤CAR-T细胞治疗中的多学科联合诊治

详细信息

Multidisciplinary treatment combination in CAR-T therapy for refractory primary central nerves system diffuse large B-cell lymphoma

More Information
  • 本文介绍1例原发中枢弥漫大B细胞淋巴瘤合并重症感染并气管插管患者的多学科联合诊治(MDT)过程。该患者初期起病隐匿,诊断困难,辗转于神经内科、神经外科、血液科就诊,经过多次腰椎穿刺检查后最终确诊原发中枢神经系统弥漫大B细胞淋巴瘤,给予多次化疗后未能获得完全缓解,且合并重症感染并行气管插管治疗,患者再次转至我院血液科治疗。经过我院MDT讨论,为患者制定了一个全面详尽的治疗方案,包括桥接化疗、CAR-T细胞治疗,在此过程中淋巴瘤获得完全缓解,患者一般状况明显好转。该患者的诊治过程体现了MDT在难治性原发中枢神经系统弥漫大B细胞淋巴瘤患者中,尤其是合并复杂并发症的患者中存在重要的价值,对于明确患者诊断、提供最佳治疗方案、改变预后结局,发挥着决定性的作用。
  • 加载中
  • [1]

    Primary Central Nervous System Lymphoma(PCNSL)[EB/OL]. [2022-07-25]. https://www.nccn.org/patients/guidelines/content/PDF/pcnsl-patient.pdf

    [2]

    Batchelor T, Carson K, O'Neill A, et al. Treatment of Primary CNS Lymphoma with Methotrexate and De-ferred Radiotherapy: A Report of NABTT 96-07[J]. J Clin Oncol, 2003, 21(6): 1044-1049. doi: 10.1200/JCO.2003.03.036

    [3]

    Zou Y, Tong J, Leng H, et al. Diagnostic Value of Using 18F-FDG PET and PET/CT in Immuno-competent Patients with Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis[J]. Oncotarget, 2017, 8(25): 41518-41528. doi: 10.18632/oncotarget.17456

    [4]

    Grommes C, Nayak L, Tun HW, et al. Introduction of Novel Agents in the Treatment of Primary CNS Lymphoma[J]. Neuro-Oncology, 2019, 21(3): 306-313. doi: 10.1093/neuonc/noy193

    [5]

    Ghesquieres H, Ferlay C, Sebban C, et al. Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase Ⅱ study of the Groupe d'Etude des Lymphomes de l'Adulte(GELA)[J]. Ann Oncol, 2010, 21(4): 842-850. doi: 10.1093/annonc/mdp529

    [6]

    Omuro A, Chinot O, Taillandier L, et al. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEFGOELAMS randomised phase 2 trial[J]. Lancet Haematol, 2015, 2(6): 251-259. doi: 10.1016/S2352-3026(15)00074-5

    [7]

    Ferreri AJ, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab(MATRix regimen)in patients with primary CNS lymphoma: results of the first randomization of the International Extranodal Lymphoma Study Group-32(IELSG32) phase 2 trial[J]. Lancet Haematol, 2016, 3(5): 217-227.

    [8]

    Abramson JS, McGree B, Noyes S, et al. Anti-CD19 CAR T cells in CNS diffuse large B-cell lymphoma[J]. N Engl J Med, 2017, 377(8): 783-784. doi: 10.1056/NEJMc1704610

    [9]

    Alcantara M, Houillier C, Blonski M, et al. CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network[J]. Blood, 2022, 139(5): 792-796. doi: 10.1182/blood.2021012932

  • 加载中
计量
  • 文章访问数:  2060
  • PDF下载数:  878
  • 施引文献:  0
出版历程
收稿日期:  2022-08-01
刊出日期:  2022-09-01

目录